Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30861066.
- Also identified by DOI 10.1093/cid/ciz159.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prolonged courses of isavuconazole (ISA) are increasingly utilized in immunocompromised patients. Toxicities have been reported with long-term use of the other triazoles. We report the first real-life tolerability data in 50 patients with hematologic malignancy receiving ≥6 months of ISA. ISA was well tolerated in our ill patient population.
Medical subject headings
- Hematologic Neoplasms
- Nitriles
- Pyridines
- Triazoles